Account
Insider Insights
20.06.2022
NICE trials new proportionate approach to increase

The aim of this trial is to increase capacity, with a goal of a 20% increase by 2023-24.

Read more
Insider Insights
15.06.2022
NHS announces further details of subscription styl

The subscription-style payment model for antibiotics announced by NICE in April 2022 will be capped ...

Read more
Insider Insights
25.05.2022
Access consortium recommended by NICE in draft gui

The Access Consortium is made up of regulatory authorities including the UK, Australia, Canada, Sing...

Read more
Insider Insights
19.05.2022
AstraZenecas Imfinzi approved for routine NHS use

Durvalumab was previously made available to NHS patients in 2019 through the Cancer Drugs Fund (CDF)...

Read more
Articles
28.04.2022
Regulators are giving early access to medicines, b...

Introduction Early Access Programs (EAPs) help to give people with life threatening or seriously deb...

Read more
Insider Insights
27.04.2022
Optimised NICE recommendations

According to the ABPI, over the last 20 years, 82% of technology appraisal recommendations have been...

Read more
Insider Insights
19.04.2022
Payment model to be launched for antibiotics

The UK looks set to become the first country in the world to use a subscription-style payment model ...

Read more
Articles
19.04.2022
Could Brexit lead to earlier access to medicines f...

Introduction Following Brexit, regulatory oversight in the UK has switched from the European Medicin...

Read more
Insider Insights
24.03.2022
“First of its kind” MAA leads to NICE approval

The draft final guidance reverses previous guidance issued in November 2021 rejecting the drug for r...

Read more
Insider Insights
21.03.2022
Early access agreement

Patients in England will be the first in Europe to have access to Takeda’s Exkivity (mobocertinib)...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.